MICA: The North West England MRC Fellowship Scheme in Clinical Pharmacology and Therapeutics

Lead Research Organisation: University of Liverpool
Department Name: Institute of Translational Medicine

Abstract

Clinical pharmacologists are physicians and scientists whose focus is developing and understanding existing and new drug therapies; they work in a variety of settings in academia, the NHS, industry and government. In the clinical setting, they work directly with patients, participate in trials, and investigate how patients respond to drugs, including why certain patients develop side effects to drugs. The total number of academic clinical pharmacologists trained in the UK is small, and there is an imperative to continue to train more clinical pharmacologists and other specialists with expertise in clinical pharmacology who can work between academia, healthcare and industry. In 2010, the Government recognised that the provision of high quality-care and better interaction with Industry requires clinicians to be familiar with the relevant practices in clinical pharmacology. The universities of Liverpool and Manchester, in collaboration with industry partners, were awarded funding from the MRC to address this unmet need in clinical pharmacology: The North West England MRC Clinical Research Training Fellowship Programme in Clinical Pharmacology and Therapeutics. This programme has allowed 13 clinical fellows (high flying trainee doctors), rigorously selected from across all medical specialties e.g. dermatology, rheumatology, paediatrics etc., to study for PhDs on a variety of clinical pharmacology related research topics such as drug safety and stratified medicine - matching the right drug to the right patient. In addition to their research work the fellows received without walls training with industry and modular training in key aspects of clinical pharmacology. The programme has been a tremendous success with 56 scientific journal publications, 21 conference presentations, 13 prizes and interactions with 61 NHS Trusts. All fellows will also get a PhD.

We now wish to renew the scheme with the MRC and with 4 industry partners - Lilly, Novartis, Roche and UCB Pharma, to appoint 13 more fellows. The previous successful format and structure will be retained as will joint leadership from the two universities. Refinements to the programme include: increasing the number of industry partners thereby allowing us to cover more therapeutic areas including cancer; lengthening of the recruitment process to give potential fellows, their supervisors and industry representatives more time to develop research projects with strong alignment; identification of a lead industry partner for each fellow from the beginning of the programme to develop a partnership from the outset; ensuring, where possible, that fellows can spend up to one year with the industry partner at their site(s) performing different aspects of their project. These changes will enhance fellows' training with industry, and also increase the input provided by industry in individual projects. There will be very strong patient and public engagement (as in the current scheme) with involvement of patients in the planning of research proposals, a number of public lectures and involvement of fellows at events such as the Manchester Science Spectacular.

The Fellowship Programme will go some way to producing academics with expertise in clinical pharmacology and helping to optimise the safe, targeted prescribing of existing drugs and the development of new therapies for human disease.

Technical Summary

There is an imperative to train more clinical pharmacologists who can work between UK academia, healthcare and industry. This was acknowledged by the Office of Life Science in 2010, which led to the award of the North West England MRC Clinical Research Training Fellowship Programme in Clinical Pharmacology and Therapeutics (CPT). The Programme has trained 13 high-calibre clinical Fellows, from a variety of specialties, to PhD level. The Fellowships have resulted in an impressive list of outputs including publications, further grant funding and active patient and public engagement. Most have graduated to academic posts. We now wish to renew the programme. The scheme is strengthened by involving 4 major pharmaceutical companies (Lilly, Novartis, Roche and UCB Pharma) who will contribute both in cash and in kind. These industry partners will provide without walls training for the Fellows, enhanced by increasing the potential for alignment between their therapeutic areas and the interests of the Fellows. All Fellows will receive modular training in CPT. We will continue with a robust two-stage recruitment process (with MRC input), but will modify it by increasing the time-interval between the two stages to allow for more input from Industry into individual projects. The Fellows will have an industry co-supervisor and spend 3-12 months at partner sites. The thematic areas chosen are consistent with: (a) the academic strengths of the two Universities; and (b) the significant investments from the MRC into the MRC Centre for Drug Safety Science, and the Stratified Medicine and Molecular Pathology initiatives.

Planned Impact

Clinical Pharmacology is a speciality vital for UK healthcare and industry and should be at the very heart of the drug development process. The beneficiaries are:
1.Academia
- Publishing in high-impact journals will ensure that the science-base grows in the pharmacological responses to medicines (1-5 yr)
- The Fellowship scheme will improve our ability to bring together diverse experts in order to enhance our specific research programmes and address the need for more medically qualified clinical pharmacologists (1-5 yr)
- Other national/ international academics will gain from collaborative links with Fellows, either from access to clinical samples, access to cross-cutting technologies, or access to intellectual expertise (1-5 yr)
- The scheme will produce 'rounded' clinical pharmacologists with sought-after skill-sets, who will make a valuable and practical contribution to the continued growth of this cross-disciplinary medical research activity in the UK (5-7 yr)
- Training of these Fellows will enhance experimental medicines capabilities within the UK, an area identified as vital for future innovation and economic growth (5-7 yr)

2.Health Care Providers
- The scheme will increase capacity in Clinical Pharmacology and Therapeutics and help to reduce a well-documented critical skills gap in the NHS (5-7 yr)
- Newly-trained Fellows will promote and support more effective prescribing within the NHS (5+ yr)
- Data produced by Fellows will inform prognostic and diagnostic testing strategies that will lead to safer and more cost-effective personalisation of therapies (5+ yr)
- Scientific outputs from Fellows will improve the benefit-risk profile of medicines and reduce the financial burden associated with adverse drug reactions or lack of efficacy (5+ yr)
- Fellows will enhance capabilities for early phase trials within NHS organisations through the development of clinical research facilities and interactions with Industry, ultimately improving access to novel medicines for patients (5+ yr)
- Fellows will increase capabilities in precision medicine in the UK NHS, an area vital for future healthcare (5+ yr)

3.Pharmaceutical Industry
- The skills gap in clinical pharmacology is acutely felt in the pharmaceutical sector and so the capacity-building aspect of the scheme will lead to an innovative partnership between academic and pharma, integrating academic expertise from early development of drugs through to postmarketing (5-7 yr)
- The "without-walls" focus of training for the Clinical Fellows will help to build new collaborations and drive novel scientific plans between pharma, the NHS and academia (1-5 yr)
- Scientific outputs from Fellows will be used to develop drugs with better benefit-risk profiles, with associated reputational and economic benefits to the industry (5+ yr)

4.Diagnostics Sector
- There will be new opportunities for the commercialisation of diagnostic and prognostic testing strategies leading to an improvement in the benefit:risk of drugs, especially in complex patient populations, with knock-on economic benefits to the sector (5+ yr)
- It will enhance the development of diagnostics for precision medicine (5+ yr)

5.Regulatory Authorities
- Fellows' scientific outputs will better inform drug regulators and will thereby contribute towards better evidence-based policy making at a global level (5+ yr)
- It will increase the number of experts in clinical pharmacology to act on advisory bodies for the regulators, thereby enhancing national and international influence (5+ yr)

6.Patients and the General Public
- Improving the benefit-risk of existing and new medicines will clearly have a major impact on enhancement of the clinical care of patients, improving clinical outcome and quality of life (5+ yr)
- The publics interest in drug safety and precision medicine is high and Fellows will educate the public in their perception of the benefits and risks associated with medicines (1-5 yr)

Publications

10 25 50

 
Description Co-Chair of the Royal College of Physicians in Edinburgh Trainee and Members Committee - Anna Olsson-Brown
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
Impact As co-chair of the CPE TMC Anna is involved in all of the committees activities. This includes a representation role both nationally and internationally. Anna represents the RCPE at federation and Academy of Royal Colleges. In addition to this the college are involved in education, careers and communication with junior doctors, sevior doctors, members of alied health professionals and the general public
URL https://www.rcpe.ac.uk/college/trainees-and-members-committee
 
Guideline Title Emergency Guideline: Acute management of the endocrine complications of checkpoint inhibitor therapy
Description Development of guidelines for the management of endocrine disorders secondary to immuno-oncology checkpoint inhibition - Anna Olsson-Brown
Geographic Reach National 
Policy Influence Type Citation in clinical guidelines
 
Description Dr Boyd is a member of the JRCPTB Specialty Advisory Committee for Infection Training in the UK
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
Impact Dr Boyd is the national Infectious Diseases trainee representative. She sits on the JRCPTB Specialty Advisory Committee for Infection Training in the UK. She represents trainees nationally and is part of a wider group who develops curricula, makes recommendations for postgraduate specialty training in Infection, and troubleshoots the delivery of infection training at a national level.
URL https://www.jrcptb.org.uk/about-us/sac-members
 
Description Elected Member of the Trainees and Members Committee at the Royal College of Physicians in Edinburgh (Dr Anna Olsson-Brown)
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
Impact The committee has three main foci - Representation at National level pertaining to post-graduate training and representation; Education resulting in the composition and delivery of national lecture series "Evening Medical Updates" and a yearly symposium "Medical Trainees Conference" and Careers and Communication which is focused on the development and support of post graduate training within the medical specialties.
 
Description Expert Panel Meeting for UK NEQAS PD-L1 Scheme
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
Impact NEQAS (National external quality assurance scheme) is the national UK body in ensuring the highest standards of technical proficiency for various medical diagnostic and clinical tests. Participation in this scheme was for technical quality assurance of PD-L1 testing and feedback helps maintain consistency for testing across labs in the UK
URL https://www.ukneqasiccish.org/pd-l1-pilot-methodology-data-entry/
 
Description JRCPTB Management and Policy (MAP) Board Member - Anna Olsson-Brown
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
Impact Anna acts as one of the trainee representatives at the JRCPTB management and policy board. The remit of the board is to address all educational issues pertaining to the medical training of doctors in physicianly specialities including those in academic training posts and those training LTFT.
 
Description Member of LHP Oncology Education Group (Dr Anna Olsson-Brown)
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Membership of a guideline committee
Impact This group has contributed to a number of training days (Regional and National) and supports an Acute Oncology Master level module at the University of Liverpool. The next educational session pertains to Oncology and Genomics.
 
Description Member of UKONS Oncology Working Group (Dr Anna Olsson-Brown)
Geographic Reach National 
Policy Influence Type Membership of a guideline committee
 
Description Participation in a advisory committee - Dr Boyd is a member of the JRCPTB Specialty Advisory Committee for Infection Training in the UK (2016-2019)
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
Impact My involvement in this national committee has allowed me to be involved in developing and troubleshooting the implementation of a national curriculum for infection trainees, which aims to improve the education and skills of the workforce in addition to improving the efficiency and effectiveness of public service delivery.
 
Description Steering Group member leading to the publication of national guidelines - UKONS Inital Management Guidelines
Geographic Reach National 
Policy Influence Type Membership of a guideline committee
Impact This guideline has unified a national approach to the management of immune related adverse events as a result of oncological immunotherapies streamlining management and optimising patient outcomes from toxicity
URL https://www.nwcscnsenate.nhs.uk/files/9815/2759/2181/UKONS_AO_management_guidelines_-_Rev._March_202...
 
Description BTOG Scholarship Bursary
Amount £300 (GBP)
Organisation British Thoracic Oncology Group 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2019 
End 01/2019
 
Description British Association of Dermatologists and Dowling Club
Amount £1,000 (GBP)
Organisation British Association of Dermatologists (BAD) 
Sector Learned Society
Country United Kingdom
Start 04/2019 
End 04/2019
 
Description European Academy of Dermatology and Venereology - Travel Grant
Amount € 1,000 (EUR)
Organisation European Academy of Dermatology and Venereology 
Sector Charity/Non Profit
Country Switzerland
Start 09/2018 
End 09/2018
 
Description European Society of Medical Oncology Merit Award
Amount € 400 (EUR)
Organisation European Society of Medical Oncology (ESMO) 
Sector Charity/Non Profit
Country Switzerland
Start 12/2018 
End 12/2018
 
Description MRC Discovery Medicine North (DiMeN) Flexible Funding Grant
Amount £2,950 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 11/2018 
End 02/2019
 
Description Wellcome Trust Public Engagement Grant (Umair Khan & Jing Xu)
Amount £900 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 02/2019 
End 09/2019
 
Title HYST Sample collection in Immunotherapy patients 
Description My research project has led to the development of a database and biobank of samples collected from patients recieving immunotherapies and from those experiencing toxicity. This has occurred within the study entitled: A Mechanistic Investigation into Drug and Chemical induced hypersensitivity reactions REC Ref 12/NW/0525. Samples and clinical data is supported by CRF collection. Arms of the study include: Longitudinal Cohort Study - Pretreatment samples and then periodic samples over 4 months Longitudinal Case/Control Study - Recruited at the time of an immune related adverse events secondary to checkpoint inhibitors and periodic sampling following this End Organ studies - Three arms with blood and tissue samples taken in a paired fashion at the point of toxicity. Arms include Thyroiditis (Double pass FNA), Skin biopsy (6mm punch biopsy) and colitis (12 bite biopsies) 
Type Of Material Database/Collection of data 
Year Produced 2017 
Provided To Others? Yes  
Impact The outputs from this database and samples is currently being established with work ongoing 
 
Title MolGen Immunotherapy 
Description Samples for DNA extraction and clinical data collection associated with CRF and electronic database in patients receiving immunotherapy. Patients are collected and categorised by the experience of immune related adverse events or no evidence of toxicity. This is conducted under the Molecular Genetics of Adverse Drug Reaction Study Ethics Research Number 09/H1005/28. Recruitment is available nationally and is portfolio adopted. 
Type Of Material Database/Collection of data 
Year Produced 2017 
Provided To Others? Yes  
Impact Currently under analysis 
 
Description Clatterbridge Cancer Centre - Anna Olsson-Brown 
Organisation The Clatterbridge Cancer Centre NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution Establishment of the HYST and MolGen study at CCC. Working with their biobank team
Collaborator Contribution Establishment of the HYST and MolGen study at CCC. Expanding the role of the CCC biobank
Impact Ongoing work
Start Year 2016
 
Description Collaboration with Roche 
Organisation Roche Pharmaceuticals
Country Global 
Sector Private 
PI Contribution I developed a PhD fellowship project with Roche as part of the MRC Clinical Pharmacology Fellowship. This involved several discussions and meeting for their input into the project and culminated in me being awarded the MRC fellowship.
Collaborator Contribution Insight into the project and expert opinion on the clinical pharmacology aspect of the project.
Impact This collaboration led to the MRC Clinical Pharmacology fellowship. I will spend 6 months at Roche to learn industry focused clinical pharmacology and work with the bioinformatics team to work on my data of integrating different 'omics' datasets.
Start Year 2017
 
Description Immune related Colitis -Anna Olsson-Brown 
Organisation King's College London
Department MRC Centre for Transplantation
Country United Kingdom 
Sector Public 
PI Contribution Provision of samples. Working in partnership with their research team to conduct flow cytometry analysis on samples related to immune related colitis from oncological immunotherapy.
Collaborator Contribution Working in partnership with the research team to conduct flow cytometry analysis on samples related to immune related colitis from oncological immunotherapy.
Impact Work Ongoing
Start Year 2017
 
Description Immunome Protein Array for Autoantibody detection in the circumstance of oncology immunotherapy toxicity (Munir Pirmohamed/ Anna Olsson-Brown) 
Organisation Sengenics
Country Singapore 
Sector Private 
PI Contribution Study design and sample provision for pilot study
Collaborator Contribution provision of specific test for pilot study
Impact pending
Start Year 2016
 
Description Immunotherapy Induced Gastrointestinal Immune-related adverse events 
Organisation University of Oxford
Department Translational Gastroenterology Unit (TDU)
Country United Kingdom 
Sector Academic/University 
PI Contribution Collaboration working on the transcriptomic and cellular changes seen in patients receiving checkpoint inhibitors who have/have not developed colitis
Collaborator Contribution Undertaking flow cytometry and nanostring analysis of samples
Impact Publication currently under review
Start Year 2018
 
Description Multiomics 
Organisation University of Liverpool
Department Institute of Integrative Biology
Country United Kingdom 
Sector Academic/University 
PI Contribution Developed the PhD project and collaborated with Institute of Integrative Biology (IIB) to develop the advanced bioinformatics part of the project to integrate proteomic datasets with genomics, epigenomics and transcriptomics.
Collaborator Contribution Expert input into how to write the grant proposal for the MRC fellowship and plan of action.
Impact Obtained the MRC Clinical Pharmacology PhD fellowship.
Start Year 2017
 
Description Northern Oncology Collaboration for Healthcare Research (NOTCH) 
Organisation Belfast City Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution I am currently Vice-Chair of this multicentre research collaboration focused on delivering large scale real world health research and currently lead a project looking into real world incidence and management of immune related adverse events secondary to checkpoint inhibitors
Collaborator Contribution All partners have representative members on a collaboration board. The current Chair is situated in Leeds. All partners contribute to all projects with different leads for different projects at different centres
Impact Poster presentation at NCRI National Cancer Conference
Start Year 2018
 
Description Northern Oncology Collaboration for Healthcare Research (NOTCH) 
Organisation Leeds Teaching Hospitals NHS Trust
Country United Kingdom 
Sector Public 
PI Contribution I am currently Vice-Chair of this multicentre research collaboration focused on delivering large scale real world health research and currently lead a project looking into real world incidence and management of immune related adverse events secondary to checkpoint inhibitors
Collaborator Contribution All partners have representative members on a collaboration board. The current Chair is situated in Leeds. All partners contribute to all projects with different leads for different projects at different centres
Impact Poster presentation at NCRI National Cancer Conference
Start Year 2018
 
Description Northern Oncology Collaboration for Healthcare Research (NOTCH) 
Organisation Newcastle upon Tyne Hospitals NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution I am currently Vice-Chair of this multicentre research collaboration focused on delivering large scale real world health research and currently lead a project looking into real world incidence and management of immune related adverse events secondary to checkpoint inhibitors
Collaborator Contribution All partners have representative members on a collaboration board. The current Chair is situated in Leeds. All partners contribute to all projects with different leads for different projects at different centres
Impact Poster presentation at NCRI National Cancer Conference
Start Year 2018
 
Description Northern Oncology Collaboration for Healthcare Research (NOTCH) 
Organisation Sheffield Teaching Hospitals NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution I am currently Vice-Chair of this multicentre research collaboration focused on delivering large scale real world health research and currently lead a project looking into real world incidence and management of immune related adverse events secondary to checkpoint inhibitors
Collaborator Contribution All partners have representative members on a collaboration board. The current Chair is situated in Leeds. All partners contribute to all projects with different leads for different projects at different centres
Impact Poster presentation at NCRI National Cancer Conference
Start Year 2018
 
Description Northern Oncology Collaboration for Healthcare Research (NOTCH) 
Organisation The Christie NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution I am currently Vice-Chair of this multicentre research collaboration focused on delivering large scale real world health research and currently lead a project looking into real world incidence and management of immune related adverse events secondary to checkpoint inhibitors
Collaborator Contribution All partners have representative members on a collaboration board. The current Chair is situated in Leeds. All partners contribute to all projects with different leads for different projects at different centres
Impact Poster presentation at NCRI National Cancer Conference
Start Year 2018
 
Description Northern Oncology Collaboration for Healthcare Research (NOTCH) 
Organisation The Clatterbridge Cancer Centre NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution I am currently Vice-Chair of this multicentre research collaboration focused on delivering large scale real world health research and currently lead a project looking into real world incidence and management of immune related adverse events secondary to checkpoint inhibitors
Collaborator Contribution All partners have representative members on a collaboration board. The current Chair is situated in Leeds. All partners contribute to all projects with different leads for different projects at different centres
Impact Poster presentation at NCRI National Cancer Conference
Start Year 2018
 
Description PhD supervision - Prof Mark Coles to Dr Anna Olsson-Brown 
Organisation University of Oxford
Department Kennedy Institute of Rheumatology
Country United Kingdom 
Sector Academic/University 
PI Contribution Anna is Prof Mark Coles PhD student
Collaborator Contribution Prof Mark Coles provides PhD supervision to Dr Anna Olsson-Brown
Impact Poster presentations presented by Anna Olsson-Brown at ISOP and ASCO Immuno-oncology Symposium
Start Year 2016
 
Description Sengenic Immunome Protein Array - Anna Olsson-Brown 
Organisation Sengenics
Country Singapore 
Sector Private 
PI Contribution Collection and provision of anonymised samples for investigation into the immune related adverse events following oncological immunotherapy
Collaborator Contribution Evaluation of serum samples using the Immunome protein array platform determining the presence of autoantibodies. They are also providing the data analysis for the sample pilot
Impact No outputs as yet. Collaboration just concluding the initial round of analysis
Start Year 2017
 
Description CDSS workshop presentation: Overview of safety profile of immune-stimulating agents - Anna Olsson-Brown 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Anna gave a presentation regarding the evolving safety concerns of immune checkpoint blockade and some initial early signals regarding pathology/ toxicity
Year(s) Of Engagement Activity 2018
URL http://www.bionow.co.uk/events/safetyofimmunecheckpointinhibitors.aspx
 
Description Checkpoint inhibitor induced thyroid immune related adverse events; ISOP poster -Anna Olsson-Brown 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Anna presented a poster at this international meeting
Year(s) Of Engagement Activity 2017
URL http://isop2017liverpool.org/
 
Description Conference: Health is Wealth (Dr Anna Olsson-Brown) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact To share information. Stimulated panel debate within the session.
Year(s) Of Engagement Activity 2017
URL http://www.liverpoollep.org/events/health-wealth-2017-conference/
 
Description Dermatology patient focus group 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Patients, carers and/or patient groups
Results and Impact Set up dermatology research focus group in Mersey area to discuss potential studies of interest and to refine studies in place. Stimulate discussion between clinicians, patients and research team.
Year(s) Of Engagement Activity 2018
 
Description ISOP Oral Presentation: Pharmacovigilance of anti-cancer medicines: opportunities and - Anna Olsson-Brown 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Anna gave anoral presentation reviewing the incidence and impact of immune related adverse events associated with immune checkpoint inhibitors. Talk given on Wednesday 18/10/18 at this international conference
Year(s) Of Engagement Activity 2017
URL http://isop2017liverpool.org/programme/
 
Description Interview for BBC 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Raised general awareness of the research and clinical services we have established for the management of immune related adverse events
Year(s) Of Engagement Activity 2018
 
Description Invited Speaker at the ACP Immunotherapy Workshop 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Research and early phase trials in Immunotherapy: Challenges and Innovations. Invited Oral Presentation. Association of Cancer Physicians Immunotherapy Workshop. (December 2018)
Year(s) Of Engagement Activity 2018
URL http://www.theacp.org.uk/userfiles/file/calendar/2018/acp-immunotherapy-workshop-2018_-draft-agenda-...
 
Description MRC Festival of Science "Ask a Scientist"/"Im a Scientist, Get me Out of Here) 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Schools
Results and Impact Throughout the month of June participated in an online series of questions and live chat sessions that allowed school children from around the country to ask a variety of questions to scientists and to discuss matters of varying topics.
Year(s) Of Engagement Activity 2018
URL https://mrcfestival2018.imascientist.org.uk
 
Description Macmillan Primary Care Conference: Immunotherapy workshop - Anna Olsson-Brown 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Anna held an workshop highlighting and raising the profile of immunotherapy toxicity (so called immune related adverse events)
Year(s) Of Engagement Activity 2017
 
Description Manchester Science Spectacular - Anna Olsson-Brown 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Anna was a member of a team from the University of Liverpool. Focus on explaining the action of immunotherapy to members of the public using innovative ideas and a tradional tble top skittles alley
Year(s) Of Engagement Activity 2017
URL http://www.engagement.manchester.ac.uk/highlights/manchester_science_festival/science_spectacular/in...
 
Description Manchester Science Spectacular 2017 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Clinical Research Fellows on the North West England MRC Fellowship Scheme joined with several PhD students from the MRC Centre for Drug Safety Science to take part in the 2017 University of Manchester Science Spectacular, an annual event that forms part of the Manchester Science Festival. The Research Fellows and the PhD students ran an activity stand called 'Marvellous Medicine' which explained a little bit about where drugs come from and how clinicians make decisions about how to use them. However the main focus of this year's activity was to explain the use of immunotherapy in treating cancer using a skittles game. The Science Spectacular is normally attended by approx. 1,500 people and we estimate that approximately 100 guests visited the activity stand. The verbal feedback we received on the day from both adults and children was very positive.
Year(s) Of Engagement Activity 2017
URL http://www.engagement.manchester.ac.uk/highlights/manchester_science_festival/science_spectacular/
 
Description Manchester Science Spectacular 2018 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact The Manchester Science Spectacular is an annual event that forms part of the Manchester Science Festival. In 2018 six of the scheme's Fellows took part in this event (Sara Boyd, Umair Khan, Jing Xu, Christopher Darlow, Alexander Haragan and Kim Su). The Fellows ran table top activities aimed at a family audience which sought to explain personalised medicine and immunotherapy. The science spectacular attracted well over a thousand visitors and between 100 and 150 people visited the 'Marvellous Medicine' stand. Children and their parents enjoyed the activities and many asked several questions.
Year(s) Of Engagement Activity 2018
URL http://www.engagement.manchester.ac.uk/highlights/manchester_science_festival/science_spectacular/
 
Description Media release in the huffington post 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Publication in the Huffington Post to raise awareness of immunotherapy treatment, toxicities and management
Year(s) Of Engagement Activity 2018
URL https://www.huffingtonpost.co.uk/entry/exclusive-i-thought-i-wouldnt-see-another-christmas-but-mirac...
 
Description Member of the organising committee and sessional chair: Early researcher Symposium - Anna Olsson-Brown 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Postgraduate students
Results and Impact Anna was a member of the scientific committee and chair of the Personalised Medicine and Drug Safety session. Assessment and decisions regarding abstracts and invites to poster and oral presenters. Running of the session on the day. Member of the judging panel for oral and poster presentation,
Year(s) Of Engagement Activity 2017
URL https://ecslivuni.wordpress.com/scientific-committee/
 
Description NHS 70 Event (Alexander Haragan, Umair Khan and Anna Olsson Brown) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact As part of the 70th Anniversary of the NHS the local NHS Trust invited researchers to set up information stands in communal areas of the hospital to provide an opportunity for patients and members of the public to learn more about medical research that is happening locally. Three Liverpool based Fellows took part in this event and spoke to members of the pubic about advances in cancer medicine (Immunotherapy) and personalised health. Participants were also able to play a table top bowling game which acted as a metaphor for how immunotherapy works and this was very well received with several participants saying it had really helped them to understand the concept.
Year(s) Of Engagement Activity 2018
 
Description NWCRC Seminar Series 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Other audiences
Results and Impact A talk as part of the North West Cancer Research Centre (NWCRC) seminar series entitled ""Immunotherapy in cancer treatment - current successes and future perspectives"

This reached local and regional students, academics, researchers and medical professionals. Much debate was generated./
Year(s) Of Engagement Activity 2018
URL https://www.liverpool.ac.uk/nwcrc/events/
 
Description Organisation of Seminar from External Speakers - Sengenics (Dr Anna Olsson-Brown; Dr Neil French) 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Postgraduate students
Results and Impact To share information. Stimulated debate and questions within the attendees.
Year(s) Of Engagement Activity 2017
 
Description Organiser of CDSS workshop: Safety of immune checkpoint inhibitors - Anna Olsson-Brown 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact cAnna was the o-organiser of CDSS workshop on safety of immune-oncology agents. Involved in programme development, inviting speakers and running of the event
Year(s) Of Engagement Activity 2018
URL http://www.bionow.co.uk/events/safetyofimmunecheckpointinhibitors.aspx
 
Description Participation in a advisory committee - Dr Boyd is a member of the JRCPTB Specialty Advisory Committee for Infection Training in the UK (2016-2019) 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Participation in a advisory committee - Dr Boyd is a member of the JRCPTB Specialty Advisory Committee for Infection Training in the UK (2016-2019). This committee meets several times per year to discuss the training of Infectious Diseases and Microbiology clinicians. Dr Boyd is enabled to represent the views of her peers and also to inform key decision makers in Infection training. She is enabled to advocate for research training for all infection trainees, which will lead to greater societal benefit and a more capable clinical workforce.
Year(s) Of Engagement Activity 2016,2017,2018,2019
 
Description Participation in a professional council - Dr Boyd is a the trainee representative for the British Infection Association in the UK (2016-2019) 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Dr Boyd is the trainee representative for the British Infection Association. This role allows her to debate and advocate for the BIA (a registered charity) to fund medical research and it also allows her to partake in organising conferences and public involvement areas, for example she administrates the BIA twitter page. These activities have wide reach and allow her to disseminate research findings and influence decision making at a high level.
Year(s) Of Engagement Activity 2016,2017,2018,2019
 
Description Participation in the Manchester Science Festival 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact The Manchester Science Festival was a one day event that allowed us to showcase our pharmacology research to a wide public audience and to field questions relating to research as a broader topic.
Year(s) Of Engagement Activity 2018
 
Description Participation on a media video regarding medical oncology - Anna Olsson-Brown 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Anna Participated in media video regarding a career in medical oncology
Year(s) Of Engagement Activity 2017
URL http://ecancer.org/video/6359/why-choose-medical-oncology--trainee-perspective.php
 
Description Pint of Science 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Pint of Science is a non-profit organisation that brings scientists to local pubs to discuss their latest research and findings with you. I was one of 3 speakers talking in the broader theme of "Our Body" and talked with an audience of varied and wide background of the specifics of my project and how immunotherapy changes and is changing medical and oncological care, and how my project and these related schemes are actively benefiting the wider public and improving this care. After my 25 minute presentation on the talk I took a Q&A session and over the rest of the evening fielded more questions from interested attendees.
Year(s) Of Engagement Activity 2018
URL https://pintofscience.co.uk
 
Description Poster Presentation at NCRI - NOTCH Collaboration 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Jones C, Olsson-Brown A, Gault A et al. The Northern Oncology Trainees Collaborative for Healthcare Research. Poster Presentation National Cancer Research Institute Annual Conference. (November 2018)
Year(s) Of Engagement Activity 2018
 
Description Poster Presentation at NCRI on irAE Colitis 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Olsson-Brown A, Sacco J, Corrie P, Steven N et al. A National Snapshot of real-world combination checkpoint inhibitor induced immune-related colitis. Poster Presentation National Cancer Research Institute Annual Conference. (November 2018)
Year(s) Of Engagement Activity 2018
 
Description Poster presentation at the ASCO SITC Clinical Immuno-Oncology Symposium: Two distinct clinical trajectories of inflammatory thyroiditis evoked by checkpoint blockade in malignant melanoma - Anna Olsson-Brown 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Anna presented a poster to the entire delegation on Thursday 25th January 2018 at the international immune-oncology symposium at the Mariott Hotel, San Francisco
Year(s) Of Engagement Activity 2018
URL https://meetinglibrary.asco.org/browse-meetings/2018%20ASCO-SITC%20Clinical%20Immuno-Oncology%20Symp...
 
Description Public Engagement for the MRC at the Science Spectacular, Manchester (20/10/18) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact The MRC clinical pharmacology programme participated in the Science Spectacular - a science festival in Manchester aimed at engaging the public with current research in a variety of disciplines. The stand we ran had a multitude of different activities relating to personalised medicine to explain the importance and potential of this to families and children attending the event.
Year(s) Of Engagement Activity 2018
 
Description UKONS National Conference - Poster Presentation - Anna Olsson-Brown 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Anna was the co-author of a poster presentation - Abstract 7 Developing guidelines to standardise the management of immunotherapy toxicities. Upoton J, Olsson-Brown A
Year(s) Of Engagement Activity 2017
URL https://rcni.com/sites/rcn_nspace/files/UKONS%20booklet%202017%20WEB%20FINAL.pdf
 
Description Wikipedia Event - A Level students 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Schools
Results and Impact Engagement with local schools, A Level Students participated in activity. The event entitled 'A celebration of Women in Science'; Wikipedia edit-a-thon, involved 21 A Level students working with five female scientists to edit the Wikipedia pages of female scientists past and present. The event was supported by Wikimedia and Dr Jess Wade who provided tuition to the students and academic staff in how to edit Wikipedia. Female academic scientist also gave inspirational talks to the students. The activity was part of the University of Liverpool's Athena Swan agenda and was organised by Angela Foxcroft (Fellowship Scheme Co-ordinator) and Dr Lauren Walker (Former fellow of the Fellowship Scheme).
Year(s) Of Engagement Activity 2018
 
Description World Cancer Day Public engagement 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Patients, carers and/or patient groups
Results and Impact As part of world cancer day, a stall about research activity was set up by University of Liverpool. I volunteered where using a mini bowling set game demonstrated the concept of drug resistance to patients. We also had general discussion about the research I carry out and general direction of research.
Year(s) Of Engagement Activity 2019